Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes.
Ashutosh K Tewari, Reza Mehrazin, Peter Wiklund et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review synthesized long-term outcomes in untreated or conservatively managed prostate cancer, drawing on 15 studies and 43,127 patients with median follow-up of 15–30 years. Outcomes varied substantially by tumor grade: 10-year prostate cancer-specific survival ranged from >95% for Gleason 6 tumors to <60% for Gleason 8-10 disease. Grade Group 1 tumors had <5% metastatic risk over 15-20 years, while Grade Groups 4-5 were associated with median disease-specific survival <5 years. Progression accelerated after 15 years, and competing mortality was substantial among men diagnosed after age 75.
Key findings
- Ten-year prostate cancer-specific survival ranged from >95% for Gleason 6 tumors to <60% for Gleason 8-10 disease.
- Grade Group 1 tumors had <5% metastatic risk over 15-20 years; Grade Groups 4-5 had median disease-specific survival <5 years.
- Progression accelerated markedly after 15 years across risk groups.
- Among men diagnosed after age 75, 10-year non-cancer mortality was ~57-60%, regardless of tumor grade.
Why it matters
The review highlights tumor grade and time horizon as central to interpreting the natural history of untreated prostate cancer. Low-grade disease may remain indolent for many years, whereas high-grade disease can progress rapidly; competing mortality also affects the potential relevance of cancer outcomes in older men. These differences provide context for weighing surveillance and treatment decisions.
What to keep in mind
The review combined heterogeneous observational cohorts, population registries, and meta-analyses using different staging and grading systems, which may limit comparability across reported outcomes.